Grant: Discovery Grants Program - Individual
Université de Montréal
$44,000.00
Biological modeling to bridge in vitro and epidemiological studies: A new approach for animal-free chemical risk assessment
EF 2023-24
Résumé
There are more than 85,000 chemicals on the market, and hundreds more entering every year. Little is known about the toxicity of most of these chemicals, many of which are routinely found in blood, urine and breast milk samples from the general population, indicating widespread exposure. To asses the risks associated with human exposure to these chemicals, scientists have traditionally determined acceptable exposure levels based on tests conducted in laboratory animals. However, animal tests are expensive and time-consuming, and often poorly predict adverse effects in humans. The status quo for chemical risk assessment is therefore unacceptable. Recognizing the limitations and ethical considerations associated with animal testing, the U.S. Environmental Protection Agency and the Liberal Party of Canada both indicated they plan to phase out animal toxicity testing by 2035. Thus, there is an urgent need for alternative methods that are faster, cheaper, and provide human-relevant information for risk assessment. The overarching objective of my research program is to develop and evaluate the accuracy of predictive tools to assess the risks of chemical exposures in humans without the use of animals. This will be carried out through the development of mathematical models to extrapolate acceptable exposure levels based on results from in vitro toxicity tests on human cells. Namely, my research team will work on models to estimate chemical concentrations over time in in vitro systems (i.e., dynamic in vitro mass-balance models), models to predict the activity/properties of chemicals based on their structure (i.e., quantitative structure-activity relationship models), and models to estimate blood/tissue levels in humans exposed to chemicals (i.e., physiologically-based pharmacokinetic models). Through case studies on different chemicals, we will evaluate the accuracy of this approach to estimate acceptable exposure levels by comparing them to results from epidemiological studies in humans. This unique research program will provide key bridging data to facilitate the transition away from animal-centered chemical risk assessment. Through continuous collaborations with policy-makers, we will maximize the uptake of knowledge and tools for their implementation by regulatory agencies (e.g., Health Canada), which will ultimately lead to more robust and ethical chemical risk assessment.
Programme
Discovery Grants Program - Individual
Bénéficiaire
Emplacement
Quebec, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
NSERC's Awards Data
Tel que publié
Application id
RGPIN-2023-03477
Name nom
Verner, Marc-André
Department département
Santé environnementale et santé au travail - Santé environnementale et santé au travail
Organization id
63
Institution établissement
Université de Montréal
Province en
Québec
Province fr
Québec
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2023
Competition year année de concours
2023
Award amount
44000
Program id
RGPIN
Program name en
Discovery Grants Program - Individual
Program name fr
Programme de subventions à la découverte - individuelles
Group en
DISCOVERY RESEARCH
Group fr
RECHERCHE AXÉE SUR LA DÉCOUVERTE
Committee code
1502
Committee name en
Biological Systems and Functions
Committee name fr
Systèmes et fonctions biologiques
Area of application code
406
Area of application group en
Environment
Area of application group fr
Environnement
Area of application en
Pollutants and toxic agents (waste, use 902)
Area of application fr
Polluants et agents toxiques (déchets, utiliser 902)
Research subject code
9999
Research subject group en
Not available
Research subject group fr
Not available
Research subject en
Non disponible
Research subject fr
Non disponible
Application title
Biological modeling to bridge in vitro and epidemiological studies: A new approach for animal-free chemical risk assessment
Keyword
In Vitro Assays; Mass-Balance Modeling; New Approach Methods; Physiologically-Based Pharmacokinetic (PBPK) Modeling; Quantitative Structure-Activity Relationships (QSAR); Risk Assessment
Application summary
There are more than 85,000 chemicals on the market, and hundreds more entering every year. Little is known about the toxicity of most of these chemicals, many of which are routinely found in blood, urine and breast milk samples from the general population, indicating widespread exposure. To asses the risks associated with human exposure to these chemicals, scientists have traditionally determined acceptable exposure levels based on tests conducted in laboratory animals. However, animal tests are expensive and time-consuming, and often poorly predict adverse effects in humans. The status quo for chemical risk assessment is therefore unacceptable. Recognizing the limitations and ethical considerations associated with animal testing, the U.S. Environmental Protection Agency and the Liberal Party of Canada both indicated they plan to phase out animal toxicity testing by 2035. Thus, there is an urgent need for alternative methods that are faster, cheaper, and provide human-relevant information for risk assessment. The overarching objective of my research program is to develop and evaluate the accuracy of predictive tools to assess the risks of chemical exposures in humans without the use of animals. This will be carried out through the development of mathematical models to extrapolate acceptable exposure levels based on results from in vitro toxicity tests on human cells. Namely, my research team will work on models to estimate chemical concentrations over time in in vitro systems (i.e., dynamic in vitro mass-balance models), models to predict the activity/properties of chemicals based on their structure (i.e., quantitative structure-activity relationship models), and models to estimate blood/tissue levels in humans exposed to chemicals (i.e., physiologically-based pharmacokinetic models). Through case studies on different chemicals, we will evaluate the accuracy of this approach to estimate acceptable exposure levels by comparing them to results from epidemiological studies in humans. This unique research program will provide key bridging data to facilitate the transition away from animal-centered chemical risk assessment. Through continuous collaborations with policy-makers, we will maximize the uptake of knowledge and tools for their implementation by regulatory agencies (e.g., Health Canada), which will ultimately lead to more robust and ethical chemical risk assessment.